Net

Digerati Technologies Reports Revenue of $7.56 Million for Second Quarter Fiscal Year 2024

Retrieved on: 
Monday, March 25, 2024
Administration, Tax, Conference, Three Months, CFO, EPS, SAN, Support, Nature, Loss, Adjustment, Depreciation, GAAP, Net, Unified communications, OTCQB

SAN ANTONIO, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Digerati Technologies, Inc. (OTCQB: DTGI) ("Digerati" or the "Company"), a provider of cloud services specializing in Unified Communications as a Service (“UCaas") solutions for the small to medium-sized business (“SMB”) market, announced today financial results for the three and six months ended January 31, 2024, the Company’s second quarter for its Fiscal Year 2024.

Key Points: 
  • Key Financial Highlights for the Three Months Ended January 31, 2024 (Compared to Three Months Ended January 31, 2023)
    Revenue decreased 5% to $7.565 million compared to $7.941 million.
  • Net loss attributable to Digerati’s common shareholders was $3.556 million, compared to net income attributable to Digerati’s common shareholders of $0.220 million.
  • Six Months ended January 31, 2024, Compared to Six Months ended January 31, 2023
    Revenue for the six months ended January 31, 2024, was $15.219 million, a decrease of $0.852 million, or 5%, compared to $16.071 million for the six months ended January 31, 2023.
  • Operating loss for the six months ended January 31, 2024, was $2.446 million, an increase of $0.481 million or 24%, compared to $1.965 million for the six months ended January 31, 2023.

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
GAAP, Research, Net, Investment, Instil, Video game

DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.

Key Points: 
  • DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update.
  • Research and development expenses were $2.0 million and $39.6 million for the fourth quarter and full year ended December 31, 2023, respectively, compared to $20.7 million and $141.1 million for the fourth quarter and full year ended December 31, 2022, respectively.
  • Restructuring and impairment charges were $0.2 million and $72.0 million for the fourth quarter and full year ended December 31, 2023, respectively, compared to $23.2 million for the fourth quarter and full year ended December 31, 2022.
  • Please refer to the below reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

Cibus Reports Fourth Quarter Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, Farmer, Gene editing, Entrepreneurship, HT1, Seed, HT2, Net, Bayer, PSR, Breeding, CBUS, WOSR, European Parliament, Agriculture

We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.

Key Points: 
  • We've made significant progress on the commercial front with several advancements of these developed traits, including transfers to customers.
  • This vote was a significant milestone for our entire industry and is a crucial step that will help Cibus usher in the gene editing era."
  • 2 Cibus Powered™ is the internal Cibus trait standard that ensures each Cibus trait meets minimum efficacy and quality assurance commercial requirements.
  • Cibus will host a live webcast, Thursday, March 21, 2024, at 4:30 p.m. Eastern Standard Time to discuss its fourth quarter 2023 financial results and provide a business update.

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, American Heart Association, Letter, Arrhythmia, Refusal, Offering, Paroxysmal supraventricular tachycardia, Safety, Atrial fibrillation, New Drug Application, Patient, Shanda, NDA, Aes, Science, Net, RTF, Investment, AHA, Milestone, Revera, FDA, Pharmaceutical industry

MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update.

Key Points: 
  • - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting expected mid-2024
    MONTREAL and CHARLOTTE, N.C., March 21, 2024 (GLOBE NEWSWIRE) --  Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update.
  • There was no revenue recorded for the fourth quarter of 2023, compared with $3.5 million the fourth quarter of 2022.
  • Commercial expense for the fourth quarter of 2023 was $5.0 million, compared with $2.6 million for the prior year period.
  • For the fourth quarter of 2023, net loss was $13.6 million, compared to $13.2 million for the prior year period.

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
AYA, Research, Remuneration, Civil service commission, Administration, Conference, Net, Growth, Young adult, Fennec, FENC, Patient, Into, G&A, NCCN, Adolescence, Marketing, MHRA, TSX, European Commission, FDA, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update.

Key Points: 
  • ET ~
    RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today reported its financial results for the fiscal year ended December 31, 2023 and provided a business update.
  • PEDMARQSI was granted EU marketing authorization by the European Commission in June 2023, and received UK approval from the MHRA in October 2023.
  • Achieved PEDMARK net product revenue of approximately $9 million and $21 million for the fourth quarter and full year 2023, respectively.
  • Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023
    Net Sales – Net product sales of $21.3 million in fiscal 2023 compared to $1.5 million in 2022.

17 Education & Technology Group Inc. Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Research, PIN, Growth, H.10, RMB, Net, Translation, Investment, GAAP, Income tax, USD, Marketing, Bank

Sales and marketing expenses in 2023 were RMB101.3 million (US$14.3 million), representing a year-over-year increase of 28.0% from RMB79.1 million in 2022.

Key Points: 
  • Sales and marketing expenses in 2023 were RMB101.3 million (US$14.3 million), representing a year-over-year increase of 28.0% from RMB79.1 million in 2022.
  • General and administrative expenses in 2023 were RMB154.3 million (US$21.7 million), representing a year-over-year decrease of 30.2% from RMB221.0 million in 2022.
  • Loss from operations as a percentage of net revenues in 2023 was negative 200.5%, compared with negative 39.8% in 2022.
  • Net loss in 2023 was RMB311.8 million (US$43.9 million), representing a year-over-year increase of 75.3% from RMB177.9 million in 2022.

UP Fintech Holding Limited Reports Unaudited Fourth Quarter And Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 20, 2024
Communication, Conference, HK, Asset, IPO, Fintech, ADS, Net, Investment, RSVP, Depreciation, GAAP

For the fourth quarter of 2023, the Company’s weighted average number of ADSs used in calculating non-GAAP net income per ADS – diluted was 157,931,785.

Key Points: 
  • For the fourth quarter of 2023, the Company’s weighted average number of ADSs used in calculating non-GAAP net income per ADS – diluted was 157,931,785.
  • Further, these non-GAAP financial measures may differ from the non-GAAP financial information used by other companies, including peer companies, and therefore their comparability may be limited.
  • Investors are encouraged to review these historical non-GAAP financial measures in light of the most directly comparable GAAP measures.
  • We encourage investors and others to review our financial information in its entirety and not rely on a single financial measure.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Retrieved on: 
Monday, March 18, 2024
Department of Defence, Food and Drug Administration, Burn, Learning, Patient, BVA, Sale, Nature, Statistics, Investment, Note, LVAD, ICU, Duke, Form, Blood volume, NIH, Heart failure, Length of stay, American College, Operation, Hand, Health, Food, Sepsis, Acceleration, Letter, Proxy, Knowledge, Research, Hospital, Acquisition, CLIA, Clinical study design, Family, FDA, Consultant, Annual general meeting, Diagnosis, RCT, Financial statement, Growth, Syncope, Mortality, National Institutes of Health, Nursing care plan, Bangladesh Technical Education Board, Net, Government, Physician, Medicine, Pharmaceutical industry

We have never been more focused on our mission and goals. Every team member at Daxor sees both the remarkable strides the company has made over the past year solidifying its position as the global leader in blood volume measurement technology and the promise of what our rapid expansion means for both the company and the tens of millions of patients whose care we are eager to significantly improve. In every area 2023 and the strong start of 2024 has shown substantial progress for the company -- in revenue growth, new customer acquisitions, increasing utilization of our products by existing customers, next generation systems completed and under Food and Drug Administration (FDA) review, positive clinical studies, new patents granted and pending, successful National Institutes of Health (NIH) grant awards, Department of Defense (DoD) contracts awarded, and further research and development for groundbreaking products set to launch in subsequent fiscal years. I will detail below more in these areas but first wish to review why our company’s mission to commercialize the products that enable optimal patient care is so vital.

Key Points: 
  • Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh.
  • Many of these markers are costly, some are invasive, and none are accurate – in contrast to Daxor’s proven 98% accurate system.
  • Care teams cannot effectively treat what they do not correctly diagnose, so our rapid accurate diagnostic test is a game-changer.
  • Daxor has been reporting as an investment company under the Investment Company Act of 1940 since January 1, 2012.

Imperial Reports 2023 Financial Results

Retrieved on: 
Friday, March 15, 2024
Tax, Capital expenditure, Copper, Gold, Acquisition, London Bullion Market Association, Public expenditure, Capital, Transport, Huckleberry, Depreciation, Net, CDN, Mining

Revenue from the Mount Polley mine in 2023 was $233.3 million compared to $42.7 million in 2022, an increase of $190.6 million.

Key Points: 
  • Revenue from the Mount Polley mine in 2023 was $233.3 million compared to $42.7 million in 2022, an increase of $190.6 million.
  • Revenue from the Red Chris mine in 2023 was $109.8 million compared to $129.5 million in 2022, a decrease of $19.7 million.
  • The London Metals Exchange cash settlement copper price per pound averaged US$3.85 in 2023 compared to US$4.00 in 2022.
  • London Bullion Market Association, London gold price per troy ounce averaged US$1,943 in 2023 compared to US$1,801 in 2022.

ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update

Retrieved on: 
Thursday, March 14, 2024
SIV, Data, Combination, EGFR, Property, SPI, Patient, Sale, Attention deficit hyperactivity disorder, Syndrome, Lung cancer, IND, Myelodysplastic syndrome, Bank statement, Investment, Note, European, TNBC, ADHD, GAP, BioLite, DSM-IV codes, GMP, Investigational New Drug, MDS, Common stock, UCSF, NSCLC, Dietary supplement, Research, Good manufacturing practice, Cancer, University, Security (finance), Pancreatic cancer, Drug development, TGA, FDA, Map, Consultant, Variable, Toxicity, Metastasis, Patent, MDD, Triple-negative breast cancer, License, Long-term care, Net, US FDA, Pharmaceutical industry

As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).

Key Points: 
  • As per the respective agreements, each of ABVC and BioLite received 23 million shares of AIBL stock (with an expected value of $10 per share).
  • The Company entered a cooperation agreement on August 14, 2023, with Zhong Hui Lian He Ji Tuan, Ltd. (“Zhonghui”).
  • On February 06, 2024, ABVC acquired an additional real estate asset via an equity transfer of 703,495 shares at $3.50 per share to develop plant factories for ABVC’s botanical pipeline.
  • ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pharmaceutical, and biotechnology industries.